Article
Oncology
Jonas Willmann, Selma Adilovic, Eugenia Vlaskou Badra, Sebastian M. Christ, Maiwand Ahmadsei, Stephanie Tanadini-Lang, Michael Mayinger, Matthias Guckenberger, Nicolaus Andratschke
Summary: This study compared the characteristics and outcomes of patients with oligometastatic disease (OMD) treated with a single course and repeat stereotactic body radiotherapy (SBRT). The results showed that although patients treated with repeat SBRT had shorter progression-free survival (PFS), they had longer overall survival (OS). Therefore, the role of repeat SBRT for OMD patients deserves further investigation.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Siven Chinniah, Bradley Stish, Brian A. Costello, Lance Pagliaro, Daniel Childs, Fernando Quevedo, Fabrice Lucien, Alan Bryce, Sean S. Park, Jacob J. Orme
Summary: The review examines the evidence for localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. It also outlines the potential future incorporation of RT as immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
S. K. Nagpal, K. Khabra, G. Ross, A. M. Kirby
Summary: The study compared outcomes of stereotactic body radiotherapy (SBRT)-treated synchronous oligometastatic breast cancer (OMBC) with those of SBRT-treated metachronous OMBC. The results showed that SBRT was a well-tolerated treatment for OMBC with excellent local control rates regardless of synchronous or metachronous presentation. Further prospective studies are required to validate this finding.
Review
Oncology
Xiao-Yao Feng, Jing Li, Ao-Mei Li, Sheng-Hua Jing, Xi-Xu Zhu, Zhen Wang
Summary: This study retrospectively analyzed the safety and efficacy of SBRT for recurrent and oligometastatic STS. The results showed that SBRT is a safe and effective treatment, and histological grade influences local control and survival.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Pauline Lemoine, Marie Bruand, Emmanuel Kammerer, Emilie Bogart, Pauline Comte, Philippe Royer, Juliette Thariat, David Pasquier
Summary: This study aimed to evaluate the progression-free survival and local control of oligometastatic breast cancer patients treated with SBRT, showing long PFS, low toxicity, and high local control rates. Phase III studies are ongoing to further investigate the application of SBRT in breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Guillaume Virbel, David G. Cox, Anne Olland, Pierre-Emmanuel Falcoz, Clara Le Fevre, Roland Schott, Delphine Antoni, Georges Noel
Summary: Stereotactic body radiotherapy (SBRT) with a 60-Gy schedule in 8 fractions is an effective and well-tolerated treatment for patients with lung oligometastases from any solid primary tumor. It provides favorable clinical outcomes in terms of local control, progression-free survival, overall survival, and toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xiaoqin Ji, Yulu Zhao, Chenglong He, Siqi Han, Xixu Zhu, Zetian Shen, Cheng Chen, Xiaoyuan Chu
Summary: The addition of SBRT to chemotherapy has shown to improve overall survival in liver-only oligometastatic pancreatic cancer patients, especially those with primary tumor located in the head of pancreas or good performance status. Moreover, SBRT is a safe and effective method for local progression control and local symptomatic relief in patients with metastatic pancreatic cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lauren E. Henke, Jennifer A. Stanley, Clifford Robinson, Amar Srivastava, Jessika A. Contreras, Austen Curcuru, Olga L. Green, L. Stewart Massad, Lindsay Kuroki, Katherine Fuh, Andrea Hagemann, David Mutch, Carolyn McCourt, Premal Thaker, Matthew Powell, Stephanie Markovina, Perry W. Grigsby, Julie K. Schwarz, Anupama Chundury
Summary: This study evaluated the feasibility and safety of a novel radiation therapy method (SMART) for the treatment of ovarian oligometastases. The results showed that SMART was effective and safe in treating ovarian metastases in the abdomen, pelvis, and central thorax, with minimal toxicity, high rates of local control, and prolonged systemic-therapy-free survival, leading to improved quality of life for patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Oncology
Guillaume Virbel, Clara Le Fevre, Georges Noel, Delphine Antoni
Summary: Stereotactic body radiation therapy (SBRT) is an effective and safe treatment for lung metastases, particularly in oligometastatic patients with localized disease involving one to three organs. This review summarized the recent progress and evaluation results of radiotherapy for pulmonary metastasis in the past five years.
Article
Oncology
Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans Hammers, Waddah Arafat, Kevin Courtney, Isaac A. Bowman, David Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas
Summary: This study evaluated the feasibility of SAbR for patients with systemic therapy-naive oligometastatic RCC and found that SAbR can provide long-term disease control while preserving quality of life for patients.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cem Onal, Gokhan Ozyigit, Zuleyha Akgun, Banu Atalar, Sefik Igdem, Ezgi Oymak, Fulya Agaoglu, Ugur Selek, Ozan Cem Guler, Pervin Hurmuz, Teuto Zoto Mustafayev, Fadil Akyol
Summary: The study showed that stereotactic body radiotherapy (SBRT) is an effective and well-tolerated treatment option for prostate cancer patients with 5 or fewer bone-only oligometastases detected using Ga-68-PSMA PET/CT.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Health Care Sciences & Services
Giuseppe Facondo, Gianluca Vullo, Vitaliana De Sanctis, Margherita Rotondi, Riccardo Carlo Sigillo, Maurizio Valeriani, Mattia Falchetto Osti
Summary: This study retrospectively analyzed the clinical outcomes of stereotactic body radiation therapy (SBRT) for lymph node metastases from gynecological cancers. The results showed that SBRT achieved excellent tumor control with low toxicities.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
H. Greenwood, J. Hassan, K. Fife, T. V. Ajithkumar, K. Thippu Jayaprakash
Summary: Stereotactic ablative body radiotherapy (SABR) is a treatment method that delivers high doses of ionising radiation for various types of tumors. In this review, the efficacy of single-fraction SABR for different tumor types is analyzed, along with its advantages, disadvantages, and future directions.
Review
Surgery
Chai Hong Rim, Won Kyung Cho, Sunmin Park, Won Sup Yoon, Dae Sik Yang
Summary: This meta-analysis confirms the oncologic role of local ablative treatment (LAT) in treating oligometastatic nonsmall cell lung cancer, with synchronous and oligopersistent disease showing more benefit than oligoprogression/recurrence disease.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Oncology
Matthew P. Deek, Kim Van der Eecken, Philip Sutera, Rebecca A. Deek, Valerie Fonteyne, Adrianna A. Mendes, Karel Decaestecker, Ana Ponce Kiess, Nicolaas Lumen, Ryan Phillips, Aurelie De Bruycker, Mark Mishra, Zaker Rana, Jason Molitoris, Bieke Lambert, Louke Delrue, Hailun Wang, Kathryn Lowe, Sofie Verbeke, Jo Van Dorpe, Renee Bultijnck, Geert Villeirs, Kathia De Man, Filip Ameye, Daniel Y. Song, Theodore DeWeese, Channing J. Paller, Felix Y. Feng, Alexander Wyatt, Kenneth J. Pienta, Maximillian Diehn, Soren M. Bentzen, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer, Emmanuel S. Antonarakis, Tamara L. Lotan, Alejandro Berlin, Shankar Siva, Piet Ost, Phuoc T. Tran
Summary: This study presents the long-term outcomes of metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) and investigates the impact of high-risk mutations on treatment outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: Definitive chemoradiotherapy is a valuable first-line treatment for cervical esophageal squamous cell carcinoma (CESCC) with favorable oncological outcomes. Further research is needed to identify survival predictors for stage-based clinical guidelines.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Otorhinolaryngology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: The study aims to determine the oncological outcomes of surgery for cervical esophageal cancer. The results showed different survival rates between larynx preserving surgery and non-preserving surgery, and further research is needed to compare the effects of surgery and chemoradiotherapy.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Letter
Oncology
Armando De Virgilio, Andrea Costantino, Bianca Maria Festa, Giuseppe Mercante, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Andrea Marrari, Raffaele Cavina, Salvatore Marano, Carlo Castoro, Giuseppe Spriano
Summary: This study conducted a meta-analysis on the oncological outcomes of patients with cervical esophageal squamous cell carcinoma treated with chemoradiotherapy. The results showed a local-regional failure rate of 41.4% and a distant failure rate of 21.6%. The study also found that the radiotherapy dose did not significantly affect overall survival, suggesting that increasing the dose may not improve survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ciro Franzese, Beatrice Marini, Davide Baldaccini, Marco Badalamenti, Pierina Navarria, Luisa Bellu, Davide Franceschini, Tiziana Comito, Elena Clerici, Maria Ausilia Teriaca, Maria Massaro, Luciana Di Cristina, Lorenzo Lo Faro, Stefano Tomatis, Marta Scorsetti
Summary: This study confirms the efficacy and safety of SABR for oligoprogression from RCC, with the potential to prolong ongoing systemic therapy and eliminate resistant metastases.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Sabrina Rossi, Arianna Marinello, Arianna Pagliaro, Davide Franceschini, Pierina Navarria, Giovanna Finocchiaro, Luca Toschi, Marta Scorsetti, Armando Santoro
Summary: Oncogene-addicted non-small cell lung cancer patients often experience CNS metastases, leading to worse prognosis and exclusion from clinical trials. Targeted agents for ALK/ROS1/NTRK-positive NSCLC have been tested, and their intracranial efficacy is evaluated and compared based on subgroup analysis from pivotal trials.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Oncology
Pierina Navarria, Federico Pessina, Giuseppe Minniti, Ciro Franzese, Beatrice Marini, Giuseppe D'agostino, Marco Badalamenti, Luca Raspagliesi, Giacomo Reggiori, Francesca Lobefalo, Laura Fariselli, Davide Franceschini, Luisa Bellu, Elena Clerici, Valentina Pinzi, Marta Scorsetti
Summary: Around 2-15% of primary renal cell carcinoma patients will develop brain metastases. The prognosis of brain metastatic RCC patients is poor and determining the optimal local therapeutic approach is a challenge. A retrospective multi-institutional study was conducted to assess the efficacy of local treatments and identify prognostic factors. The study confirmed the efficacy and safety of SRS/HSRS and found that patients with specific characteristics had a better outcome.
Review
Health Care Sciences & Services
Ciro Franzese, Damiano Dei, Nicola Lambri, Maria Ausilia Teriaca, Marco Badalamenti, Leonardo Crespi, Stefano Tomatis, Daniele Loiacono, Pietro Mancosu, Marta Scorsetti
Summary: This review provides a comprehensive description of the applications of artificial intelligence (AI) tools in the radiotherapy (RT) process for head and neck cancer (HNC). The majority of the selected studies focused on the segmentation of organs at risk (OARs), while limited research was found on the impact of AI on clinical outcomes. It is suggested that future studies should be conducted by interdisciplinary groups, including clinicians and computer scientists, to ensure the effective alignment of AI technologies with clinical needs in RT.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Giulia Marvaso, Federico Mastroleo, Giulia Corrao, Mattia Zaffaroni, Maria Giulia Vincini, Paolo Borghetti, Francesco Cuccia, Manuela Federico, Giampaolo Montesi, Antonio Pontoriero, Davide Franceschini, Ciro Franzese, Marta Scorsetti, Barbara Alicja Jereczek-Fossa
Summary: The concept of oligometastatic state has revolutionized our understanding of cancer metastasis and progression, with ongoing research efforts to develop new treatment options. This study presents a bibliometric analysis of the oligometastatic disease/state, providing a comprehensive overview of the topic. A total of 3304 documents from 1995 to 2022 were analyzed, revealing the top keywords used by authors and identifying emerging themes and trends. This analysis serves as a valuable resource for researchers worldwide and highlights the significant scientific progress in the field of oligometastatic state.
Article
Oncology
Tiziana Comito, Maria Massaro, Maria Ausilia Teriaca, Ciro Franzese, Davide Franceschini, Pierina Navarria, Elena Clerici, Luciana Di Cristina, Anna Bertolini, Stefano Tomatis, Giacomo Reggiori, Andrea Bresolin, Silvia Bozzarelli, Lorenza Rimassa, Cristiana Bonifacio, Silvia Carrara, Armando Santoro, Alessandro Zerbi, Marta Scorsetti
Summary: This study evaluated the efficacy of stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC), and the results showed that SBRT achieved significant improvements in local control, survival, and safety.
Article
Oncology
Stefano Tomatis, Pietro Mancosu, Giacomo Reggiori, Francesca Lobefalo, Pasqualina Gallo, Nicola Lambri, Lucia Paganini, Francesco La Fauci, Andrea Bresolin, Sara Parabicoli, Marco Pelizzoli, Pierina Navarria, Ciro Franzese, Domenico Lenoci, Marta Scorsetti
Summary: This study analyzed the evolution of radiation therapy protocols over a twenty-year period and demonstrated that hypo-fractionation, supported by proper technology, can lower costs and increase patient access to advanced radiation therapy. The findings provide valuable insights for management teams and highlight the importance of patient-focused reimbursement policies.
Article
Oncology
Nicola Lambri, Simone Leopoldo Antonetti, Damiano Dei, Luisa Bellu, Stefania Bramanti, Ricardo Coimbra Brioso, Carmelo Carlo-Stella, Isabella Castiglioni, Elena Clerici, Leonardo Crespi, Chiara De Philippis, Carmela Galdieri, Daniele Loiacono, Pierina Navarria, Giacomo Reggiori, Roberto Rusconi, Stefano Tomatis, Marta Scorsetti, Pietro Mancosu
Summary: Delivery of total marrow (lymph node) irradiation (TMI/TMLI) takes longer than standard radiotherapy treatments due to patient's extremity movements. The study evaluated the reproducibility of TMI/TMLI patient's extremities in order to find the best positioning and minimize unwanted movements.
Article
Oncology
Ciro Franzese, Stefano Tomatis, Sofia Paola Bianchi, Marco Pelizzoli, Maria Ausilia Teriaca, Marco Badalamenti, Tiziana Comito, Elena Clerici, Davide Franceschini, Pierina Navarria, Luciana Di Cristina, Damiano Dei, Carmela Galdieri, Giacomo Reggiori, Pietro Mancosu, Marta Scorsetti
Summary: Adaptive radiotherapy can help manage anatomical changes in head-neck cancer patients during radiotherapy and ensure adequate dose coverage and organ protection. This study investigated the effects of adaptive radiotherapy on patients treated with volumetric-modulated arc radiation therapy compared to simulated non-adaptive plans.